

Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor

Early data suggest molecules are stable and may be delivered orally

SAN DIEGO, California, November 27, 2017 /PRNewswire/ --

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has initiated in vivo and ex vivo assessments to determine the effects of some of the Company's NR2F6 small molecule agonists in live rats and in tissues derived from humans and rats. Key attributes that are being measured include pH, plasma and liver microsomal stability, along with pharmacokinetics.

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity. The program also aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system..

"Initial studies are quite positive. Our compounds are stable at pH 2 and 7, stable in rat and human plasma, additionally one of our compounds shows very nice pharmacokinetics with an oral or intravenous half-life of about 2.5 hrs," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "Getting this data early in the process informs us of any liabilities the compounds may have which we would need to address via medicinal chemistry. So far, these molecules look like they will be orally deliverable and will not require too much more tweaking before we can start testing them for efficacy."

"I am very pleased that we have entered the phase of development where we are now testing these drugs in vivo and ex vivo," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "These experiments we are currently involved with now will determine the path we proceed with going forward."

About Regen BioPharma Inc.:

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at <http://www.regenbiopharmainc.com>.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION

Regen BioPharma Inc.

David R. Koos, Ph.D.

Chairman & Chief Executive Officer

+1-619-702-1404 Phone

+1-619-330-2328 Fax

<http://www.regenbiopharma.com>

david.koos@regenbiopharma.com

SOURCE Regen BioPharma, Inc.